SCHEDULE: Pfizer's Allogene Stake Dips to 9.0% Amid Share Dilution
Beneficial Ownership Update
Pfizer Inc. reported a decrease in its beneficial ownership of Allogene Therapeutics, Inc. common stock to 9.0%, solely due to an increase in Allogene's outstanding shares.
Summary
- Pfizer Inc. updated its beneficial ownership in Allogene Therapeutics, Inc. to 9.0% of common stock.
- This represents 22,032,040 shares beneficially owned by Pfizer.
- The decrease in percentage ownership is solely attributed to an increase in Allogene Therapeutics' total outstanding shares, which were reported as 224,730,144 as of November 4, 2025.
- No changes were reported regarding Pfizer's identity, source of funds, purpose of transaction, or arrangements with Allogene Therapeutics.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive update. While Pfizer's percentage stake is diluted, it's not due to divestment, and the underlying reason (Allogene's increased outstanding shares) could imply successful capital raising or strategic share issuance by Allogene.
Positives
- Pfizer maintains a significant strategic stake in Allogene Therapeutics, indicating continued interest in the company's prospects.
- The decrease in percentage ownership is not due to Pfizer selling shares, but rather Allogene's share issuance, which could imply Allogene successfully raised capital or issued shares for other strategic purposes.
Negatives
- Pfizer's percentage ownership in Allogene Therapeutics has been diluted from a previously higher percentage (implied by prior amendments) to 9.0%.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding future performance or strategic direction.
Industry Context
StockSavvy.ai notes that a decrease in a major pharmaceutical company's percentage stake in a biotech firm, even if due to dilution rather than divestment, can sometimes signal a shift in strategic focus or a natural progression as the smaller company matures and raises capital independently. However, Pfizer's continued holding of a substantial number of shares suggests an ongoing strategic interest in Allogene's therapeutic pipeline, which is common in the highly collaborative and capital-intensive biotechnology sector.
Stakeholder Impact
- Shareholders (Allogene): Existing shareholders of Allogene Therapeutics have experienced dilution of their ownership percentage due to the increase in outstanding shares.
- Shareholders (Pfizer): Pfizer's investment in Allogene Therapeutics now represents a smaller percentage of the company, though the absolute number of shares held remains the same.
Key Dates
| Date | Description |
|---|---|
| October 22, 2018 | Original Schedule 13D filed by Pfizer regarding Allogene Therapeutics. |
| September 17, 2021 | Amendment No. 1 to Schedule 13D filed. |
| April 7, 2022 | Amendment No. 2 to Schedule 13D filed. |
| October 25, 2023 | Amendment No. 3 to Schedule 13D filed. |
| November 4, 2025 | Date Allogene Therapeutics' common stock outstanding (224,730,144 shares) was reported in its Form 10-Q. |
| November 6, 2025 | Date of event requiring this filing, corresponding to Allogene Therapeutics' Form 10-Q filing for the quarterly period ended September 30, 2025. |
| February 13, 2026 | Signature date of this Amendment No. 4 to Schedule 13D. |
Recommendation
holdThe filing primarily reports a passive dilution of Pfizer's stake in Allogene due to Allogene's increased share count, not an active divestment by Pfizer. This suggests Pfizer maintains its strategic interest without altering its investment thesis based on this specific disclosure. For investors, this update does not provide new information warranting a change in investment strategy for either Pfizer or Allogene, assuming the underlying reason for Allogene's share increase (e.g., capital raise) was already known or expected.
Keywords
Pfizer, Allogene Therapeutics, ALLO, PFE, Schedule 13D, Beneficial Ownership, Equity Stake, Biotechnology, Pharmaceuticals, Investment, Share Dilution
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.